251 related articles for article (PubMed ID: 21565858)
21. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
22. Tertiary hyperparathyroidism resistant to cinacalcet treatment.
Okada M; Tominaga Y; Izumi K; Nobata H; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Nanmoku K; Watarai T; Uchida K
Ther Apher Dial; 2011 Jun; 15 Suppl 1():33-7. PubMed ID: 21595850
[TBL] [Abstract][Full Text] [Related]
23. Use of ultrasound to assess the response to therapy for secondary hyperparathyroidism.
Meola M; Petrucci I; Colombini E; Barsotti G
Am J Kidney Dis; 2011 Sep; 58(3):485-91. PubMed ID: 21715073
[TBL] [Abstract][Full Text] [Related]
24. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
[TBL] [Abstract][Full Text] [Related]
25. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
[TBL] [Abstract][Full Text] [Related]
26. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
27. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.
Yamamoto M; Ogata H; Mizobuchi M; Yoshida N; Kumata-Maeta C; Koiwa F; Shishido K; Kinugasa E
Clin Exp Nephrol; 2012 Apr; 16(2):292-9. PubMed ID: 22011886
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with cinacalcet HCl.
Ureña Torres P
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
[TBL] [Abstract][Full Text] [Related]
29. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
30. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy.
Tominaga Y; Matsuoka S; Sato T; Uno N; Goto N; Katayama A; Haba T;
Ther Apher Dial; 2007 Aug; 11(4):266-73. PubMed ID: 17661832
[TBL] [Abstract][Full Text] [Related]
31. Relationship between parathyroid oxyphil cell proportion and clinical characteristics of patients with chronic kidney disease.
Ding Y; Zou Q; Jin Y; Zhou J; Wang H
Int Urol Nephrol; 2020 Jan; 52(1):155-159. PubMed ID: 31686279
[TBL] [Abstract][Full Text] [Related]
32. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis.
Martin LN; Kayath MJ; Vieira JG; Nosé-Alberti V
Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048
[TBL] [Abstract][Full Text] [Related]
33. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
34. Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size.
Hirai T; Nakashima A; Takasugi N; Yorioka N
Nephron Clin Pract; 2010; 114(3):c187-93. PubMed ID: 19955824
[TBL] [Abstract][Full Text] [Related]
35. [Histopathological study of the parathyroid gland in renal hyperparathyroidism].
Tominaga Y; Takagi H; Suzuki H; Kondo T
Nihon Geka Gakkai Zasshi; 1985 May; 86(5):630-9. PubMed ID: 4021994
[TBL] [Abstract][Full Text] [Related]
36. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
37. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
Drüeke TB
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
[TBL] [Abstract][Full Text] [Related]
38. Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism.
Matsuoka S; Tominaga Y; Sato T; Uno N; Hiramitu T; Goto N; Nagasaka T; Uchida K
Ther Apher Dial; 2008 Oct; 12(5):391-5. PubMed ID: 18937723
[TBL] [Abstract][Full Text] [Related]
39. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.
Komaba H; Nakanishi S; Fujimori A; Tanaka M; Shin J; Shibuya K; Nishioka M; Hasegawa H; Kurosawa T; Fukagawa M
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2305-14. PubMed ID: 20798251
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
